Malaria is in the headlines again with Côte d’Ivoire becoming the first country to roll out the new R21 vaccine, co-developed by the University of Oxford and Serum Institute of India using Novavax, Inc.’s Matrix-M adjuvant technology. Meantime, over 3,000 miles away in Rwanda, Novartis AG recently reflected on its role in the fight against malaria for the past 25 years and the development of next-generation treatments.
The Swiss major launched Coartem (artemether/lumefantrine), the first fixed-dose artemisinin-based combination therapy (ACT) for malaria in 1999. To date, together...


![[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space](https://web.insights.norstella-labs.com/resizer/v2/G3M6E2FVDNOJPCEXELJNOIKH64.jpg?smart=true&auth=b5d5c6477bcbd6c122699f47191cbafe560695783f500a6e7b10c4d270965bdc&width=400&height=225)


